List view / Grid view
3 June 2016 | By Victoria White, Digital Content Producer
The FDA has granted accelerated approval to Intercept Pharmaceuticals’ Ocaliva (obeticholic acid) for the treatment of primary biliary cholangitis...
2 June 2016 | By Victoria White, Digital Content Producer
Grünenthal has entered into a licensing agreement with AstraZeneca for the exclusive rights to Zurampic (lesinurad) in Europe and Latin America...
2 June 2016 | By DataApex
Clarity version 7.0 has the reorganized installation structure, which allows better access to data and a new robust system of custom units...
2 June 2016 | By Victoria White, Digital Content Producer
BioNTech has announced the publication of a study that describes the first example of a clinically relevant and systemic mRNA cancer immunotherapy...
2 June 2016 | By Victoria White, Digital Content Producer
PRIME aims to bring treatments to patients faster by enhancing the EMA’s support for the development of investigational medicines...
2 June 2016 | By Victoria White, Digital Content Producer
The EC has approved Afinitor (everolimus) for the treatment of neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease...
1 June 2016 | By Victoria White, Digital Content Producer
New data strengthen the body of research into Opdivo, hailing it as the new standard of care in recurrent metastatic renal cell carcinoma (mRCC)...
1 June 2016 | By Victoria White, Digital Content Producer
The EC has approved the use of Trevicta (paliperidone palmitate a 3-monthly injection) for the maintenance treatment of schizophrenia in adult patients...
1 June 2016 | By Victoria White, Digital Content Producer
Allergan and Medicines360 are to donate 10,000 units of Liletta to the CDC Foundation in response to the Zika virus outbreak in Puerto Rico...
1 June 2016 | By Victoria White, Digital Content Producer
The National Institute for Health and Care Excellence (NICE) has asked Janssen to set out a case for including its chronic lymphocytic leukaemia (CLL) drug ibrutinib (Imbruvica) in the Cancer Drugs Fund (CDF).
The EC has approved the subcutaneous formulation of MabThera for people with previously untreated and relapsed/refractory chronic lymphocytic leukaemia...
31 May 2016 | By Victoria White, Digital Content Producer
The European Commission (EC) has approved Imbruvica (ibrutinib) for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).
31 May 2016 | By Pharmapack
Pharmapack is a two-day exhibition and conference dedicated to pharmaceutical packaging, drug delivery and affiliated industries...
31 May 2016 | By Victoria White, Digital Content Producer
The EC has granted marketing authorisation in the European Union (EU) for Flixabi, an infliximab biosimilar referencing Remicade...
31 May 2016 | By Victoria White, Digital Content Producer
Pixium Vision has received approval from the Medicines & Healthcare products Regulatory Agency (MHRA) in the UK to initiate a clinical trial for patients who have lost sight due to retinitis pigmentosa (RP) with the IRIS II bionic vision system.
